anti-endothelial cell antibody

1.	Romitelli, Federica: 1 article (05/2008)
2.	Napolitano, Clemente: 1 article (05/2008)
3.	Iozzino, Mario: 1 article (05/2008)
4.	Cesareo, Roberto: 1 article (05/2008)
5.	De Rosa, Benedetto: 1 article (05/2008)
6.	Marsh, Clay B: 1 article (02/2007)
7.	Magro, Cynthia M: 1 article (02/2007)
8.	Ross, Patrick: 1 article (02/2007)
9.	Knight, Deborah A: 1 article (02/2007)
10.	Cowden, Daniel J: 1 article (02/2007)

Related Diseases

1.	Vasculitis (Vasculitides) 10/01/1999 - "The aim of the study was to determine the prevalence of AECA in HCV patients with or without MC-associated vasculitis, and to identify associations with clinical, immunological, virological and liver characteristics. " 06/15/1996 - "The aim of this study focused on the utilization of this technique to induce the production of anti-endothelial cells Abs (AECA) and autoimmune vasculitis in a murine model. " 06/01/2008 - "Birmingham Vasculitis Activity Scores of patients with anti-200 kDa AECA were significantly higher than in patients without. " 09/01/2007 - "In conclusion, AECA may be involved in the pathogenesis of WG, and the SAPK/JNK pathway and the endothelial inflammatory protein VAP-1 may be novel therapeutic targets for vasculitis." 12/01/2005 - "But AECA could also be found in other systemic vasculitis and SLE." Order ALL the reference details at left...
2.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/01/2006 - "To search for correlations between intima-media thickness (IMT) and high titer of AECA in patients with systemic lupus erythematosus (SLE). " 07/01/2005 - "METHODS: AECA isolated from patients with active systemic lupus erythematosus (SLE) were incubated with human umbilical vein endothelial cells (HUVECs). " 10/01/1997 - "In several diseases such as systemic lupus erythematosus and systemic vasculitis, high AECA titers are found during active disease whereas lower titers or disappearence of AECA have been reported during remission. " 04/01/1998 - "The eventual pathogenic role of AECA's is less clear, with the possible exception of rheumatoid arthritis and systemic lupus erythematosus. " 09/01/2003 - "OBJECTIVE: To determine if anti-endothelial cell antibodies (AECA) and plasma markers of endothelial cell function are related to disease severity in systemic lupus erythematosus (SLE). " Order ALL the reference details at left...
3.	Lupus Nephritis 02/01/2007 - "CONCLUSION: The strong correlations of AECA and anti-endothelial activity with lupus nephritis activity support an endothelial origin for renal complications in Taiwanese SLE patients." 02/01/2007 - "RESULTS: Significantly higher AECA (p<0.001) and anti-endothelial activities (p<0.001) were found in sera from patients with lupus nephritis compared with that from stable SLE patients or controls. " 01/01/1999 - "CONCLUSION: These results suggested that lupus nephritis patients with AECA showed a complex autoimmune disorder and provided an indirect evidence that AECA might contribute to the pathogenesis of lupus nephritis." 11/01/1993 - "These data provide indirect support for a pathogenic role for AECA in lupus nephritis." 11/01/1993 - "AECA were therefore present in most patients with acute lupus nephritis and were associated with histological evidence of active renal injury and serological evidence of endothelial cell dysfunction. " Order ALL the reference details at left...
4.	Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) 10/01/1995 - "These results suggest that cytokines and AECA are important in restructuring and destroying vessel walls in Kawasaki disease by enhancing the migration of endothelial cells, and that IVGG may be therapeutically effective for this disease by suppressing this endothelial cell migration." 11/01/1994 - "To confirm the presence of antiendothelial cell antibodies (AECA) and study the clinical value of their measurement in Kawasaki disease (KD), sera from patients with KD were assessed for binding to human umbilical vein endothelial cells (HUVEC) using a cellular based ELISA, and for complement-mediated cytotoxicity using 111In-labelled HUVEC. " 06/01/1994 - "OBJECTIVE: To assess the diagnostic potential of anti-neutrophil cytoplasmic antibodies (ANCA) and anti-endothelial cell antibodies (AECA) to distinguish early Kawasaki disease (KD) from febrile diseases resembling KD. " 03/01/1991 - "AECA have been detected in systemic lupus erythematosus, scleroderma and dermatomyositis but are also found in systemic vasculitis, Kawasaki disease, haemolytic uraemic syndrome, thrombotic thrombocytopenic purpura and renal allograft recipients at the time of rejection. " 09/01/1995 - "We studied anti-neutrophil cytoplasmic antibodies (ANCA) and anti-endothelial cell antibodies (AECA) in 58 children with acute Kawasaki disease (KD) before i.v. gamma globulin treatment, 35 children with infection and fever > 38.5 degrees C, and 48 healthy afebrile children. " Order ALL the reference details at left...
5.	Nephritis 10/01/2000 - "RESULTS: Significantly higher AECA levels were found in five patients with active disease and nephritis than in five patients with clinically inactive disease. " 08/01/1991 - "The presence of AECA conferred a positive predictive value of 0.68 for the presence of nephritis. " 08/01/1991 - "Twenty-five patients had active vasculitis at the time of assay and the highest AECA values were seen in patients with both nephritis and vasculitis. " 03/01/1998 - "RESULTS: IgA AECA were detected in seven of 15 patients with Henoch-Schönlein purpura and nephritis, but were not detected in patients without nephritis or in controls. " 08/01/1991 - "Using an ELISA, anti-endothelial cell antibodies (AECA) have been found in sera obtained at the time of renal biopsy in 46 out of 57 patients (81%) with systemic lupus erythematosus (SLE) and nephritis (mean binding index (BI) = 84% +/- 52.8) compared with 22 out of 50 SLE patients (44%) without nephritis (mean BI = 45% +/- 35.9). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antibodies
2.	Antineutrophil Cytoplasmic Antibodies (ANCA)
3.	Immunoglobulin G (IgG)
4.	Immunoglobulin A (IgA)
5.	glucuronyl glucosamine glycan sulfate (Vessel)
6.	Cytokines
7.	Antigens
8.	anti-endothelial cell antibody
9.	Complement System Proteins (Complement)
10.	von Willebrand Factor

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Homologous Transplantation (Allograft)
3.	Transplantation (Transplant Recipients)
4.	Lung Transplantation
5.	Heart Transplantation (Grafting, Heart)

Best Treatments:
Research Summary Report
on Vasculitis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 348 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>